PIEZO-101 First-in-Human Safety and Proof-of-Concept Study
NCT: NCT07671027 · NOT_YET_RECRUITING
Brief Summary
The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory efficacy using photography on the décolleté. Up to 8 participants may be enrolled to ensure 6 evaluable participants complete the study.
Frequently Asked Questions
What is PIEZO-101 First-in-Human Safety and Proof-of-Concept Study?
PIEZO-101 First-in-Human Safety and Proof-of-Concept Study is a clinical trial registered under NCT07671027. Current status: NOT_YET_RECRUITING.
What is the status of NCT07671027?
The current status of NCT07671027 (PIEZO-101 First-in-Human Safety and Proof-of-Concept Study) is: NOT_YET_RECRUITING.
When did PIEZO-101 First-in-Human Safety and Proof-of-Concept Study start?
PIEZO-101 First-in-Human Safety and Proof-of-Concept Study started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.